blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3510027

EP3510027 - DI-SUBSTITUTED PYRAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASES [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  08.09.2023
Database last updated on 30.09.2024
FormerThe patent has been granted
Status updated on  30.09.2022
FormerGrant of patent is intended
Status updated on  12.05.2022
FormerExamination is in progress
Status updated on  05.04.2022
FormerGrant of patent is intended
Status updated on  15.08.2021
FormerExamination is in progress
Status updated on  18.02.2020
FormerRequest for examination was made
Status updated on  14.06.2019
FormerThe international publication has been made
Status updated on  23.03.2018
Formerunknown
Status updated on  27.09.2017
Most recent event   Tooltip07.06.2024Lapse of the patent in a contracting state
New state(s): MC		published on 10.07.2024  [2024/28]
Applicant(s)For all designated states
FGH BioTech, Inc.
16720 Hedgecroft, 208
Houston, TX 77060 / US
[2022/14]
Former [2019/29]For all designated states
FGH Biotech, Inc.
414 Thamer Circle
Houston, Texas 77024-6918 / US
Inventor(s)01 / UESUGI, Motonari
414 Thamer Circle
Houston, TX 77024-6918 / US
02 / KINCAID, John
414 Thamer Circle
Houston, TX 77024-6918 / US
03 / HUFF, Joel
179 Spiritual Pass
Spring Branch Texas 78070 / US
 [2019/30]
Former [2019/29]01 / UESUGI, Motonari
414 Thamer Circle
Houston, TX 770204-6918 / US
02 / KINCAID, John
414 Thamer Circle
Houston, TX 77024-6918 / US
03 / HUFF, Joel
179 Spiritual Pass
Spring Branch Texas 78070 / US
Representative(s)Petty, Catrin Helen, et al
Venner Shipley LLP
200 Aldersgate
London EC1A 4HD / GB
[2019/29]
Application number, filing date17768620.107.09.2017
[2019/29]
WO2017US50562
Priority number, dateUS201662384661P07.09.2016         Original published format: US 201662384661 P
US201662438944P23.12.2016         Original published format: US 201662438944 P
[2019/29]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2018049080
Date:15.03.2018
Language:EN
[2018/11]
Type: A1 Application with search report 
No.:EP3510027
Date:17.07.2019
Language:EN
The application published by WIPO in one of the EPO official languages on 15.03.2018 takes the place of the publication of the European patent application.
[2019/29]
Type: B1 Patent specification 
No.:EP3510027
Date:02.11.2022
Language:EN
[2022/44]
Search report(s)International search report - published on:EP15.03.2018
ClassificationIPC:C07D401/04, C07D405/14, C07D401/14, A61P35/00, A61P3/04, A61P3/10, A61P9/10, A61P9/12, A61K31/4155, A61K31/4412
[2021/34]
CPC:
C07D401/14 (EP,US); A61P3/04 (EP,US); A61P3/10 (EP,US);
A61P35/00 (EP,US); A61P9/10 (EP,US); A61P9/12 (EP,US);
C07D401/04 (EP,US); C07D405/14 (EP,US) (-)
Former IPC [2019/29]C07D405/14, C07D401/04, A61K31/4155, A61K31/4412, A61P3/00, A61P35/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/29]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:DI-SUBSTITUIERTE PYRAZOLVERBINDUNGEN ZUR BEHANDLUNG VON KRANKHEITEN[2019/29]
English:DI-SUBSTITUTED PYRAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASES[2019/29]
French:COMPOSÉS DE PYRAZOLE DI-SUBSTITUÉS POUR LE TRAITEMENT DE MALADIES[2019/29]
Entry into regional phase27.03.2019National basic fee paid 
27.03.2019Designation fee(s) paid 
27.03.2019Examination fee paid 
Examination procedure27.03.2019Examination requested  [2019/29]
27.03.2019Date on which the examining division has become responsible
28.10.2019Amendment by applicant (claims and/or description)
21.02.2020Despatch of a communication from the examining division (Time limit: M06)
02.09.2020Reply to a communication from the examining division
02.12.2020Despatch of a communication from the examining division (Time limit: M04)
12.04.2021Reply to a communication from the examining division
16.08.2021Communication of intention to grant the patent
26.01.2022Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time
04.04.2022Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
13.05.2022Communication of intention to grant the patent
08.09.2022Fee for grant paid
08.09.2022Fee for publishing/printing paid
08.09.2022Receipt of the translation of the claim(s)
Opposition(s)03.08.2023No opposition filed within time limit [2023/41]
Request for further processing for:The application is deemed to be withdrawn due to failure to fulfill actions required for granting the patent
04.04.2022Request for further processing filed
04.04.2022Full payment received (date of receipt of payment)
Request granted
13.04.2022Decision despatched
Fees paidRenewal fee
27.09.2019Renewal fee patent year 03
28.09.2020Renewal fee patent year 04
27.09.2021Renewal fee patent year 05
27.09.2022Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL02.11.2022
AT02.11.2022
CZ02.11.2022
DK02.11.2022
EE02.11.2022
FI02.11.2022
HR02.11.2022
LT02.11.2022
LV02.11.2022
MC02.11.2022
NL02.11.2022
PL02.11.2022
RO02.11.2022
RS02.11.2022
SE02.11.2022
SI02.11.2022
SK02.11.2022
SM02.11.2022
NO02.02.2023
GR03.02.2023
IS02.03.2023
PT02.03.2023
[2024/28]
Former [2023/51]AL02.11.2022
AT02.11.2022
CZ02.11.2022
DK02.11.2022
EE02.11.2022
FI02.11.2022
HR02.11.2022
LT02.11.2022
LV02.11.2022
NL02.11.2022
PL02.11.2022
RO02.11.2022
RS02.11.2022
SE02.11.2022
SI02.11.2022
SK02.11.2022
SM02.11.2022
NO02.02.2023
GR03.02.2023
IS02.03.2023
PT02.03.2023
Former [2023/38]AL02.11.2022
AT02.11.2022
CZ02.11.2022
DK02.11.2022
EE02.11.2022
FI02.11.2022
HR02.11.2022
LT02.11.2022
LV02.11.2022
NL02.11.2022
PL02.11.2022
RO02.11.2022
RS02.11.2022
SE02.11.2022
SK02.11.2022
SM02.11.2022
NO02.02.2023
GR03.02.2023
IS02.03.2023
PT02.03.2023
Former [2023/37]AL02.11.2022
AT02.11.2022
CZ02.11.2022
DK02.11.2022
EE02.11.2022
FI02.11.2022
HR02.11.2022
LT02.11.2022
LV02.11.2022
NL02.11.2022
PL02.11.2022
RO02.11.2022
RS02.11.2022
SE02.11.2022
SM02.11.2022
NO02.02.2023
GR03.02.2023
IS02.03.2023
PT02.03.2023
Former [2023/35]AT02.11.2022
CZ02.11.2022
DK02.11.2022
EE02.11.2022
FI02.11.2022
HR02.11.2022
LT02.11.2022
LV02.11.2022
NL02.11.2022
PL02.11.2022
RO02.11.2022
RS02.11.2022
SE02.11.2022
SM02.11.2022
NO02.02.2023
GR03.02.2023
IS02.03.2023
PT02.03.2023
Former [2023/34]AT02.11.2022
DK02.11.2022
EE02.11.2022
FI02.11.2022
HR02.11.2022
LT02.11.2022
LV02.11.2022
NL02.11.2022
PL02.11.2022
RS02.11.2022
SE02.11.2022
SM02.11.2022
NO02.02.2023
GR03.02.2023
IS02.03.2023
PT02.03.2023
Former [2023/33]AT02.11.2022
DK02.11.2022
FI02.11.2022
HR02.11.2022
LT02.11.2022
LV02.11.2022
NL02.11.2022
PL02.11.2022
RS02.11.2022
SE02.11.2022
SM02.11.2022
NO02.02.2023
GR03.02.2023
IS02.03.2023
PT02.03.2023
Former [2023/29]AT02.11.2022
FI02.11.2022
HR02.11.2022
LT02.11.2022
LV02.11.2022
NL02.11.2022
PL02.11.2022
RS02.11.2022
SE02.11.2022
NO02.02.2023
GR03.02.2023
IS02.03.2023
PT02.03.2023
Former [2023/25]AT02.11.2022
FI02.11.2022
HR02.11.2022
LT02.11.2022
LV02.11.2022
PL02.11.2022
RS02.11.2022
SE02.11.2022
NO02.02.2023
GR03.02.2023
IS02.03.2023
PT02.03.2023
Former [2023/23]AT02.11.2022
FI02.11.2022
LT02.11.2022
LV02.11.2022
SE02.11.2022
NO02.02.2023
GR03.02.2023
PT02.03.2023
Former [2023/22]AT02.11.2022
FI02.11.2022
LT02.11.2022
SE02.11.2022
NO02.02.2023
PT02.03.2023
Former [2023/20]LT02.11.2022
NO02.02.2023
Cited inInternational search[YA]WO2008097835  (BAYLOR COLLEGE MEDICINE [US], et al) [Y] 1,2,4-33,35-38 * abstract * * examples 1-10 * * claims 1-28 * * figures 1-28 * [A] 3,34;
 [A]WO2011051961  (CADILA HEALTHCARE LTD [IN], et al) [A] 1-38 * abstract * * examples 1-420 * * claims 1-45 *;
 [YA]WO2015031710  (BAYLOR COLLEGE MEDICINE [US]) [Y] 1,2,4-33,35-38 * abstract * * page 23, lines 18-24 * * examples 1-17 * * claims 1-39 * [A] 3,34;
 [YA]US2015065519  (CHAKRAVARTY SARVAJIT [US], et al) [Y] 1,2,4-33,35-38 * abstract * * paragraphs [0010] - [0033] * * paragraphs [0048] , [0 49] , [ 363] - [0371] * * pages 29-53; tables 1-36 * [A] 3,34;
 [A]WO2016106331  (USA [US], et al) [A] 1-38 * abstract * * pages 79-383; tables 1, 2; compounds 1-828 ** claims 1-52 *
by applicantUS3536809
 US3598123
 US3845770
 US3916899
 US4008719
 US5059595
 US5073543
 US5120548
 US5354556
 US5591767
 US5639476
 US5639480
 US5674533
 US5733566
 US5739108
 US5891474
 US5922356
 US5972891
 US5980945
 US5993855
 US6045830
 US6087324
 US6113943
 US6197350
 US6248363
 US6264970
 US6267981
 US6376461
 US6419961
 US6589548
 US6613358
 US6699500
    - DEBOSE-BOYD et al., Cell, (19990000), vol. 99, no. 7, page 703
    - SAKAI et al., Cell, (19960000), vol. 85, page 1037
    - YABE et al., Proc Natl Acad Sci USA, (20020000), vol. 99, no. 20, page 12753
    - YANG et al., Cell, (20020000), vol. 110, pages 489 - 500
    - EBERLE et al., Biochimie, (20040000), vol. 86, no. 11, page 839
    - SHAO W.; ESPENSHADE PJ., Cell Metab., (20120000), vol. 16, page 414
    - ZHAO et al., Diabetes, (20140000), vol. 63, page 2464
    - PADWAL et al., Lancet, (20070000), vol. 369, page 9555
    - TAKAHASHI Y; FUKUSATO T, "Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis", World J Gastroenterol, (20141114), vol. 20, no. 42, pages 15539 - 48
    - SCHREUDER et al., World J Gastroenterol, (20080000), vol. 14, no. 16, page 2474
    - EKSTEDT et al., Hepatology, (20060000), vol. 44, no. 4, page 865
    - AJUFO et al., Lancet Diabetes Endocrinol., (20160500), vol. 4, no. 5, pages 436 - 46
    - KOLANSKY et al., Am J Cardiol., (20081201), vol. 102, no. 11, pages 1438 - 43
    - URBAN et al., JAm Coll Cardiol., (20131015), vol. 62, no. 16, pages 1401 - 8
    - ABIFADEL M et al., Nat Genet., (20030600), vol. 34, no. 2, pages 154 - 6
    - COHEN et al., Nat Genet., (20050200), vol. 37, no. 2, pages 161 - 5
    - GABITOVA et al., Clin Cancer Res, (20140000), vol. 20, no. 1, page 28
    - MENENDEZ, J. A.; LUPU, R., Nat Rev Cancer, (20070000), vol. 7, page 763
    - MEDES et al., Cancer Research, (19530000), vol. 13, page 27
    - BRUSSELMANS et al., Cancer Research, (20050000), vol. 65, pages 6719 - 6725
    - KUHAJ DA et al., Proceedings of the National Academy of Sciences of the United States of America, (20000000), vol. 97, pages 3450 - 3454
    - MENENDEZ et al., Int J Cancer, (20050000), vol. 115, pages 19 - 35
    - TANG et al., Cell Metabol, (20110000), vol. 13, page 44
    - KAMISUKI et al., Chem Biol., (20090000), vol. 16, pages 882 - 92
    - KAMISUKI et al., J. Med Chem., (20110000), vol. 54, page 4923
    - LI et al., Mol Cancer Ther., (20140000), vol. 13, no. 4, page 855
    - LI et al., Oncotarget., (20150000), vol. 6, no. 38, page 41018
    - S. M. BERGE et al., "Pharmaceutical Salts", J. Pharm. Sci., (19770000), vol. 66, doi:doi:10.1002/jps.2600660104, pages 1 - 19, XP002675560

DOI:   http://dx.doi.org/10.1002/jps.2600660104
    - LIJINSKY, Food Cosmet. Toxicol., (19820000), vol. 20, page 393
    - LIJINSKY, J. Nat. Cancer Inst., (19820000), vol. 69, page 1127
    - MANGOLD, Mutation Res., (19940000), vol. 308, page 33
    - GORDON, Drug Metab. Dispos., (19870000), vol. 15, page 589
    - ZELLO, Metabolism, (19940000), vol. 43, page 487
    - GATELY, J. Nucl. Med., (19860000), vol. 27, page 388
    - WADED, Chem. Biol. Interact., (19990000), vol. 117, page 191
    - FOSTER et al., Adv. Drug Res., (19850000), vol. 14, pages 1 - 36
    - KUSHNER et al., Can. J. Physiol. Pharmacol., (19990000), vol. 77, pages 79 - 88
    - JENS T. CARSTENSEN, Drug Stability: Principles & Practice, Marcel Dekker, (19950000), page 379 80
    - SEFTON, CRC Crit. Ref. Biomed. Eng., (19870000), vol. 14, page 201
    - BUCHWALD et al., Surgery, (19800000), vol. 88, page 507
    - SAUDEK et al., N. Engl. J. Med., (19890000), vol. 321, page 574
    - GOODSON, Medical Applications of Controlled Release, (19840000), vol. 2, pages 115 - 138
    - LANGER, Science, (19900000), vol. 249, pages 1527 - 1533
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.